Physician profile
Chung-Chieh Lo
NPI 1063705820
$11,429.87
in general payments reported to CMS, 2019-2025
28 companies · $3,179 in 2025
The $3,179 reported for 2025 was more than what 86% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.28 · 2020: $657 · 2021: $2,378 · 2022: $1,709 · 2023: $2,100 · 2024: $1,339 · 2025: $3,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,746 · Travel and Lodging: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,745.52 |
| Travel and Lodging | $872.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,982.26 | 2021-2025 | Ha Minuteman G3-R |
| Nevro Corp. | $1,454.10 | 2020-2024 | Senza |
| Abbott Laboratories | $1,427.95 | 2021-2025 | Proclaim, Eterna |
| Si-Bone, INC. | $1,113.57 | 2025 | |
| Globus Medical, INC. | $1,046.85 | 2025 | Senza, Nevro |
| Nalu Medical, INC. | $927.42 | 2021-2025 | Nalu Neurostimulation System |
| Stryker Corporation | $855.98 | 2020-2021 | |
| Painteq LLC | $633.17 | 2022-2023 | Painteq |
| Medtronic, INC. | $492.97 | 2022-2025 | Intellis Adaptivestim, Primeadvanced Surescan |
| Relievant Medsystems, INC. | $484.12 | 2022-2023 | Intracept |
| Abbvie INC. | $302.03 | 2021-2025 | |
| Spr Therapeutics, INC | $152.31 | 2020-2023 | Sprint Pns System |
| Radius Health, INC. | $67.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.86 | 2020-2021 | |
| Bioventus LLC | $60.14 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Fusion Solutions, LLC | $51.51 | 2021-2023 | |
| Biodelivery Sciences International, INC. | $46.50 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $45.93 | 2023-2025 | Belbuca, Xtampza |
| Amgen INC. | $41.65 | 2021 | |
| Averitas Pharma INC. | $31.97 | 2024 | Qutenza |
| Boston Scientific Corporation | $26.34 | 2025 | General - Pain Management |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.11 | 2025 | Relistor |
| Grt US Holding, INC. | $20.93 | 2022 | |
| Allergan, INC. | $20.10 | 2020 | |
| Horizon Therapeutics Plc | $16.43 | 2020 | |
| Medtronic USA, INC. | $15.81 | 2020 | |
| Depuy Synthes Sales INC. | $15.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chung-Chieh Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.